Supergut vs. Lemme: Two Very Different Bets on the Same Three Letters

Two products, one phrase printed on both boxes. Supergut GLP-1 Daily Support is a fruit-flavored powder you stir into water. Lemme GLP-1 Daily is two capsules you swallow with food. They're selling the same idea and they don't share a single ingredient.

That's what makes this worth doing. It isn't two versions of one formula competing on price. It's two genuinely different bets on how you'd support your body's own GLP-1, and the published research treats those bets very differently.

What's actually in each one

Supergut runs on fiber. Roughly 6 to 7 g per serving of a blend: Solnul resistant potato starch, oat beta-glucan, green banana resistant starch, and soluble maize fiber. The theory is fermentation. Your gut bacteria eat those fibers, produce short-chain fatty acids, and those metabolites nudge the L-cells that release GLP-1. We laid out that chain in our gut-brain axis primer.

Lemme runs on extracts. Three of them, fully disclosed: 400 mg Morosil red orange, 200 mg Eriomin lemon flavonoid, and 176.5 mg Supresa saffron. 776.5 mg of plant material, no fiber at all.

Fermentation versus flavonoids. Same claim, no overlap.

The GLP-1 question, measured in blood

Here's the split most buyers never see. One of these ingredient files contains trials that actually drew blood and measured circulating GLP-1. The other mostly doesn't.

Eriomin has three. Ribeiro and colleagues randomized 103 people with prediabetes into placebo or 200, 400 or 800 mg for 12 weeks. All three doses performed similarly: blood glucose down 5%, insulin resistance down 7%, GLP-1 up 15%, adiponectin up 19% (Phytotherapy Research 2019). A crossover trial by the same group put 30 people with fasting glucose above 110 mg/dL through 12 weeks of 200 mg and 12 weeks of placebo, and found glucose down 5%, HOMA-IR down 11%, and GLP-1 up 17% (Journal of Medicinal Food 2022). A third, focused on the microbiome, reported a 6% drop in hyperglycemia and a 22% increase in blood GLP-1 alongside shifts in gut bacteria (Food Science and Nutrition 2023).

Now the part the marketing skips. All three trials come from the same lab at São Paulo State University. All three ran in people with elevated blood sugar, not general shoppers. None of them measured a craving or an appetite score. And the 2019 trial states plainly that Eriomin did not change anthropometric or dietary variables, meaning GLP-1 rose 15% and body measurements stayed put. That's a real finding about a real mechanism, and it is not a weight-loss result.

The fiber side has a harder time

Supergut's mechanism is more popular and, oddly, less nailed down.

A scoping review published in July 2026 is the most current read available. De Jong and colleagues screened 1,049 papers and pulled 49 publications covering 52 randomized trials in adults, 1,085 participants total, all measuring circulating GLP-1 and satiety after a single well-defined fiber (Frontiers in Endocrinology 2026). Their summary is sobering for the category. Median sample size per study was 19 people. 71% were acute, single-dose interventions. Studies that reported a GLP-1 increase showed only a non-significant tendency to also report increased satiety, odds ratio 2.95 with a confidence interval of 0.87 to 9.98, which crosses 1.

Dextrins were the one fiber category with consistent effects on both GLP-1 and satiety. Beta-glucans, one of Supergut's four fibers, showed effects on satiety without consistently moving GLP-1 alongside it.

Then there's the resistant starch trial nobody in this category cites. White and colleagues at Pennington gave 59 adults with prediabetes and a BMI of 27 or higher 45 g a day of type-2 resistant starch for 12 weeks against an isocaloric rapidly-digestible starch control, then measured everything: visual analogue appetite scales, the Eating Inventory, a laboratory buffet meal, photographed food intake, and GLP-1, PYY and ghrelin during a mixed-meal test.

It found nothing. No effect on subjective appetite. No effect on GLP-1 (P=0.61), PYY (P=0.34) or ghrelin. No effect on energy, carbohydrate, protein or fat intake at the buffet (Journal of the Academy of Nutrition and Dietetics 2020). The dose was roughly 7 times Supergut's entire daily fiber load, the trial was NIH-funded rather than industry-funded, and the title says it out loud: resistant starch has no effect on appetite and food intake.

Two honest qualifications: that trial used high-amylose maize resistant starch rather than potato, and Supergut is a four-fiber blend rather than one isolated starch. But it's the largest and cleanest test of the underlying premise, and it came back empty.

What Supergut's headline fiber does have going for it

Solnul isn't unstudied. Bush and colleagues ran a three-arm randomized, double-blind, placebo-controlled trial of 3.5 g and 7 g daily doses over 4 weeks. The 3.5 g arm showed significantly greater increases in Bifidobacterium and Akkermansia than placebo, plus significantly fewer diarrhea- and constipation-associated bowel movements. The 7 g arm behaved about the same, which is a useful hint that more isn't better here (Nutrients 2023).

That's a genuine prebiotic result, and Akkermansia is the strain the whole GLP-1-probiotic category is built on, as we covered in our Akkermansia write-up.

Read the fine print anyway. The authors are affiliated with MSP Starch Products, which makes Solnul. The endpoints are bacterial abundance and stool consistency, not GLP-1 and not appetite. A later post hoc analysis of the same trial found neither resistant potato starch nor placebo significantly changed mean abnormal bowel symptom scores (BMC Nutrition 2024). And Supergut doesn't disclose how much Solnul sits inside its blend, so there's no way to know whether you're getting the 3.5 g that worked.

Lemme's other two extracts

Eriomin is the ingredient carrying the GLP-1 claim. The other two are doing different jobs, and the evidence thins out.

Morosil. Cardile and colleagues gave overweight healthy volunteers 400 mg a day of Moro red orange extract for 12 weeks. BMI dropped significantly from week 4, and body weight, BMI, waist and hip circumference all differed significantly from placebo (Natural Product Research 2015). It's a small, decade-old trial with a body-composition endpoint, not an appetite one, and it hasn't been replicated at anything like the scale the ingredient's marketing implies.

Saffron. Gout and colleagues randomized 60 mildly overweight women to 176.5 mg a day of a saffron extract or placebo for 8 weeks with no calorie restriction. The saffron group lost significantly more weight and reported significantly fewer snacking episodes in a daily diary (Nutrition Research 2010). This is the only trial in either product's file with something craving-adjacent as an outcome, which makes the caveat matter: that trial used Satiereal, and Lemme uses Supresa, a different branded saffron extract. The 176.5 mg number traces straight to that study. The extract doesn't. Snacking frequency was also self-recorded, which is the softest kind of endpoint in the set.

Transparency: not close

Lemme discloses all three actives at exact doses. You can take each number, find the trial, and check whether the product matches it. That's rarer in this category than it should be, and it's the single biggest thing Lemme has over Supergut.

Supergut names its four fibers but hides the split inside a proprietary blend. You get a total, 6 to 7 g, and no way to know whether the Solnul portion clears the studied 3.5 g or sits at a fraction of it. A blend that hides doses can't be checked against a study, which means the ingredient research stops being evidence about the product.

The practical difference nobody markets

6.5 g of fermentable fiber a day does something in your gut whether or not it touches GLP-1. Fermentation produces gas. That's not a defect, it's the mechanism, but it means ramping slowly matters and some people won't get along with it at all. We went through the tolerance math in is fiber the next protein and the sharper version of the same problem in the low-sugar candy piece.

Lemme has no added fiber, so there's nothing to ramp. Two capsules, no digestive adjustment period, no daily glass to mix. Whether that's an advantage depends on whether you think fiber is a side effect or the point.

On price, Supergut is the cheaper habit: about $1.50 a serving at list, $1.20 on subscription. Lemme runs $2.67 at list and $2.13 on subscription, and its money-back guarantee carries a return processing fee of roughly $10, which quietly narrows what the guarantee is worth.

The verdict

If the literal GLP-1 claim is what you're buying, Lemme has the better file. Three human trials drew blood and found increases of 15% to 22%. Nothing in Supergut's ingredient set has produced that, and the best current review of fiber and GLP-1 describes a body of small, short, inconsistent studies.

If you want a daily gut-health habit at a lower price and your stomach handles fiber, Supergut is the more sensible purchase, and its prebiotic data is real even though it points at bacteria rather than at hunger.

What neither one has is a trial on the finished product. Every claim on both boxes is assembled from individual-ingredient studies, several sponsored by the company selling the ingredient. That's the category norm, not an accusation, but it's the difference between "this formula was tested" and "these components were tested separately, in other people, at doses we may or may not match." Our scoring rubric is in the methodology.

And a 15% rise in a hormone isn't the same thing as a prescription GLP-1 medication. We worked through that pharmacology in native GLP-1 vs the drugs. The rest of the field is in our GLP-1 support category.

References

• Ribeiro CB, Ramos FM, Manthey JA, Cesar TB. Effectiveness of Eriomin in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study. Phytother Res. 2019;33(7):1921-1933. PMID 31183921
• Cesar TB, Ramos FMM, Ribeiro CB. Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial. J Med Food. 2022;25(11):1050-1058. PMID 35796695
• Ramos FMM, Ribeiro CB, Cesar TB, et al. Lemon flavonoids nutraceutical (Eriomin) attenuates prediabetes intestinal dysbiosis: A double-blind randomized controlled trial. Food Sci Nutr. 2023;11(11):7283-7295. PMID 37970408
• de Jong JCBC, Lentjes MGW, Pietersma KF, et al. Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review. Front Endocrinol. 2026;17:1880500. PMID 42528510
• White U, Peterson CM, Beyl RA, Martin CK, Ravussin E. Resistant Starch Has No Effect on Appetite and Food Intake in Individuals with Prediabetes. J Acad Nutr Diet. 2020;120(6):1034-1041. PMID 32280055
• Bush JR, Baisley J, Harding SV, Alfa MJ. Consumption of Solnul Resistant Potato Starch Produces a Prebiotic Effect in a Randomized, Placebo-Controlled Clinical Trial. Nutrients. 2023;15(7):1582. PMID 37049425
• Bush JR, Alfa MJ. Consumption of resistant potato starch produces changes in gut microbiota that correlate with improvements in abnormal bowel symptoms: a secondary analysis of a clinical trial. BMC Nutr. 2024;10(1):152. PMID 39605008
• Cardile V, Graziano ACE, Venditti A. Clinical evaluation of Moro (Citrus sinensis (L.) Osbeck) orange juice supplementation for the weight management. Nat Prod Res. 2015;29(23):2256-2260. PMID 25588369
• Gout B, Bourges C, Paineau-Dubreuil S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutr Res. 2010;30(5):305-313. PMID 20579522

Citations retrieved via PubMed. This article is for education only and isn't medical advice. Talk to your doctor before starting any supplement, especially if you're pregnant, nursing, on medication, or managing a health condition.